Mathula Thangarajh, MD, PhD, on the Potential of Gene Therapy to Address Cognitive Symptoms in Muscular Dystrophy

Video

The child neurologist and neuromuscular physician at Virginia Commonwealth University also discussed the session she chaired at the 2023 MDA Clinical and Scientific Conference.

“In terms of the gene therapy approaches right now, which are in clinical trials, we have no evidence that it will cross the blood-brain barrier unless it's delivered intrathecally. However, that being said, there are preclinical models and a couple of European researchers have shown that either antisense oligonucleotides or gene therapies could be delivered into the CNS, and it's actually able to reverse cognitive deficits, improve outcomes, and also restore dystrophin.” 

While the physical manifestations of muscular dystrophy are well known, the cognitive and behavioral effects tend to get less attention. Mathula Thangarajh, MD, PhD, a child neurologist and neuromuscular physician at Virginia Commonwealth University, chaired a session focused on these symptoms, "Making Visible the Invisible: Cognitive and Behavioral Health in Muscular Dystrophy”, at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held in Dallas, Texas, March 19-22, 2023.

In an interview with CGTLive, Thangarajh provided an overview of the presentations given during the session, which included talks on imaging methods such as structural MRI and a review of how behavioral modification should be approached. In summarizing, Thanagarajh discussed why it is important for patients to be able to more easily access behavioral health resources, especially those who are younger.

She also discussed the potential of gene therapy to address cognitive symptoms, particularly noting the limitations of administration faced by the gene therapies currently in clinical trials. Although, she explained that a different approach to neuromuscular disease with antisense oligonucleotides or gene therapies delivered directly to the central nervous system could offer hope.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.